Petros Pharmaceuticals, Inc. (PTPI)

Market Cap	3.66M
Revenue (ttm)	3.85M
Net Income (ttm)	-21.98M
Shares Out	2.11M
EPS (ttm)	-10.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	54,389
Open	1.51
Previous Close	1.50
Day's Range	1.48 - 1.75
52-Week Range	0.92 - 9.54
Beta	1.98
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2023

About PTPI

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2020
• Employees: 24
• Stock Exchange: NASDAQ
• Ticker Symbol: PTPI

Financial Performance

In 2022, PTPI's revenue was $5.99 million, a decrease of -23.29% compared to the previous year's $7.81 million. Losses were -$20.04 million, 123.0% more than in 2021.